Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Augmented SirT1 Activity Could Protect Against Osteoarthritis

By LabMedica International staff writers
Posted on 07 Dec 2011
Maintaining the activity of the enzyme SirT1 was suggested as a possible new approach to preventing or treating osteoarthritis (OA), a degenerative cartilage disease that affects millions of people around the world.

SirT1 is a histone deacetylase involved in numerous critical cell processes including DNA repair and apoptosis. More...
Previous studies have shown that exposing human osteoarthritic chondrocytes (cartilage cells) to the cytokine TNFalpha generated a stable and enzymatically inactive 75 kDa form of SirT1 (75SirT1) via cathepsin B-mediated cleavage.

Because 75SirT1 was resistant to further degradation, investigators at the Hebrew University of Jerusalem (Israel) assumed it played a distinct role in osteoarthritis (OA) pathology, which they hoped to identify in a study that was published in the October 10, 2011, online edition of the journal Arthritis and Rheumatism.

Over the course of the study OA and normal human chondrocytes were analyzed for the presence of cathepsin B and 75SirT1. Confocal imaging of SirT1 monitored its subcellular trafficking following TNFalpha stimulation.

Results showed that that 75SirT1 was exported to the cytoplasm and colocalized with the mitochondrial membrane. Consistently, immunoprecipitation and immunoblot analyses revealed that 75SirT1 was enriched in mitochondrial extracts and associated with cytochrome C, following TNFalpha stimulation. Preventing nuclear export of 75SirT1 or reducing levels of SirT1 and 75SirT1 augmented chondrocyte apoptosis in the presence of TNFalpha. Cathepsin B and 75SirT1 were elevated in OA as compared to normal chondrocytes. Additional analyses showed that normal human chondrocytes exposed to OA-derived synovial fluid generated the 75SirT1 fragment.

The results indicated that 75SirT1 promoted chondrocyte survival following exposure to proinflammatory cytokines such as TNFalpha. Drug therapies directed at boosting SirT1 production have the potential to retard or reverse OA.

“Developing a combined strategy for diagnosis and treatment, based on these data, could provide an efficient alternative for joint replacement surgery and enable susceptible individuals to experience a better quality of life for years to come,” said senior author Dr. Mona Dvir-Ginzberg, lecturer in the Institute of Dental Sciences at the Hebrew University of Jerusalem.

Related Links:
Hebrew University of Jerusalem



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.